These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 2098130

  • 1. [Bacteremia caused by Streptococcus equisimilis in a neoplastic patient treated with recombinant interleukin 2].
    Pedro-Botet ML, Ribelles Entrena N, Carrasco Miserachs I, Carles Galcerán J, Sabria-Leal M, Arnal J.
    Enferm Infecc Microbiol Clin; 1990 Dec; 8(10):659-60. PubMed ID: 2098130
    [No Abstract] [Full Text] [Related]

  • 2. Atypical contrast reactions associated with systemic interleukin-2 therapy.
    Fishman JE, Aberle DR, Moldawer NP, Belldegrun A, Figlin RA.
    AJR Am J Roentgenol; 1991 Apr; 156(4):833-4. PubMed ID: 2003450
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma.
    Aso Y, Tazaki H, Umeda T, Marumo K.
    Prog Clin Biol Res; 1989 Apr; 303():681-8. PubMed ID: 2675018
    [No Abstract] [Full Text] [Related]

  • 4. Role of interleukin-2 alone in disseminated renal cell carcinoma: an update.
    Javadpour N, Lalehzarian M.
    Prog Clin Biol Res; 1989 Apr; 303():671-9. PubMed ID: 2789391
    [No Abstract] [Full Text] [Related]

  • 5. Advances in management of disseminated renal cell carcinoma.
    Javadpour N.
    Prog Clin Biol Res; 1988 Apr; 277():85-91. PubMed ID: 3263656
    [No Abstract] [Full Text] [Related]

  • 6. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 7. Recombinant interleukin-2 and the quest for FDA approval.
    Tami JA.
    Clin Pharm; 1991 Feb; 10(2):141-2. PubMed ID: 2009733
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A, Savona S, Gafney E, Penichet KO, Lin BY, Levitt D, Ahmed T, Arlin ZA, Baskind P, Needleman D.
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Case management of the hospitalized patient receiving interleukin-2.
    Sharp E.
    Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):14-9. PubMed ID: 8210789
    [Abstract] [Full Text] [Related]

  • 13. Keynote address: perspectives on the use of interleukin-2 in cancer treatment.
    Rosenberg SA.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S2-6. PubMed ID: 9457385
    [No Abstract] [Full Text] [Related]

  • 14. Interleukin-2.
    Med Lett Drugs Ther; 1990 Sep 07; 32(826):85-6. PubMed ID: 2202892
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T.
    Cancer J Sci Am; 2000 Feb 07; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.